A Single-Center Experience With Brentuximab Vedotin in Gamma Delta T-Cell Lymphoma

Clin Lymphoma Myeloma Leuk. 2016 Feb;16(2):e15-9. doi: 10.1016/j.clml.2015.11.013. Epub 2015 Dec 1.

Authors

Rakhshandra Talpur¹, Ramya Chockalingam², Casey Wang³, Michael T Tetzlaff⁴, Madeleine Duvic³

Affiliations

¹ Department of Dermatology and Dermatopathology, University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: rtalpur@mdanderson.org.
² University of Texas Medical School, Houston, TX.
³ Department of Dermatology and Dermatopathology, University of Texas MD Anderson Cancer Center, Houston, TX.
⁴ University of Texas MD Anderson Cancer Center, Houston, TX.

PMID: 26705678
DOI: 10.1016/j.clml.2015.11.013

No abstract available

Keywords: Anaplastic large cell lymphoma; CD30 expression; Primary cutaneous lymphomas; Sensory peripheral neuropathy; Stem cell transplant.

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Aged, 80 and over
Brentuximab Vedotin
Female
Humans
Immunoconjugates / ultrastructure*
Ki-1 Antigen / metabolism
Lymphoma, T-Cell / drug therapy*
Lymphoma, T-Cell / metabolism
Middle Aged

Substances

Immunoconjugates
Ki-1 Antigen
Brentuximab Vedotin